IDEAYA Biosciences Secures IND Clearance for IDE275 (GSK959) to Initiate Phase 1 Trial in MSI-High Solid Tumors

MGI Partners with OncoDNA to Enhance Precision Oncology with Compatible Genomic Solutions

Tempus Partners with JW Pharmaceutical to Leverage Real-World Data and Biological Modeling for Enhanced R&D

Devyser Secures NMPA Approval for Devyser Compact, Expanding Genetic Testing Market in China

Qure.ai Partners with Roche’s Startup Creasphere to Enhance Healthcare Innovation in APAC

Six NHS Trusts to Deploy deepc’s AI Radiology Platform in Partnership with AI4VBC

Precision Medicine Program Marks Major Advancement in Kidney Transplant Care for Hereditary Kidney Disease Patients

Helio Genomics and Halub Medical Announce Partnership to Launch HelioLiver Dx in GCC and Middle East

Merck's KEYTRUDA® (pembrolizumab) Secures 30th European Commission Approval with Two New Indications for Gynecologic Cancers

Dyno Therapeutics Expands Collaboration with Roche to Develop Next-Generation Gene Therapies for Neurological Diseases

Philips and Medtronic Partner to Advance Stroke Care and Awareness

Qatar Precision Health Institute Unveils Genomic Data and Announces New Research Initiatives

Caris Life Sciences Partners with ECOG-ACRIN to Advance Precision Medicine in Breast Cancer Research

Celemics and Strand Life Sciences Strengthen Partnership for Enhanced NGS Analysis

Thermo Fisher Partners with Telangana Government to Launch Bioprocess Design Centre in Hyderabad

Home
/
update
/
details

NIH Launches Precision Medicine Trial for AML and MDS

NextEdge Admin

24 Oct 2024

2 min 30 sec

The National Institutes of Health (NIH) has launched the myeloMATCH trial, a precision medicine clinical study targeting specific genetic changes in cancer cells of patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Funded by the National Cancer Institute (NCI), the trial aims to accelerate the development of tailored treatments for these aggressive blood and bone marrow cancers.

According to Dr. W. Kimryn Rathmell, director of NCI, these precision trials bring cutting-edge treatments to patients across communities, promoting personalized care. Dr. Richard F. Little, NCI’s coordinator for myeloMATCH, emphasized the need for rapid identification of cancer subtypes to match treatments effectively and initiate therapy quickly after diagnosis.

Participants with newly diagnosed AML or MDS will undergo genetic testing, with treatment decisions based on the molecular features of their cancer. If a matching substudy is unavailable, patients will receive standard treatment. Those responding to initial therapy will undergo further genetic testing to identify remaining disease and guide subsequent treatment. Biomarker assays will be used to refine treatment options as the disease burden decreases.

The trial, managed by the National Clinical Trials Network and NCI’s Community Oncology Research Program, aims to enroll thousands over the next few years. Collaborators include SWOG Cancer Research Network, ECOG-ACRIN, and other leading groups.

myeloMATCH is part of a broader initiative, alongside ComboMATCH and ImmunoMATCH, to advance precision oncology. These trials build on the success of NCI-MATCH and align with the Cancer Moonshot’s goals to expand access to innovative therapies and reduce cancer deaths by 2047.